yingweiwo

Ponatinib (AP-24534; Iclusig)

Alias: AP-24534; AP24534; Ponatinib; AP 24534; Trade name: Iclusig
Cat No.:V0491 Purity: =99.14%
Ponatinib (formerly known as AP24534; trade name Iclusig) is a novel, orally bioavailable multi-targeted kinase inhibitor with potent antitumor activity.
Ponatinib (AP-24534; Iclusig)
Ponatinib (AP-24534; Iclusig) Chemical Structure CAS No.: 943319-70-8
Product category: VEGFR
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
10mg
25mg
50mg
100mg
250mg
500mg
1g
Other Sizes

Other Forms of Ponatinib (AP-24534; Iclusig):

  • Ponatinib HCl
  • Ponatinib D8
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: =99.14%

Product Description

Ponatinib (formerly known as AP24534; trade name Iclusig) is a novel, orally bioavailable multi-targeted kinase inhibitor with potent antitumor activity. In cell-free experiments, it suppresses Abl, PDGFRα, VEGFR2, FGFR1, and Src with IC50 values of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM, respectively. It may be used to treat acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in patients who have the Philadelphia chromosome (Ph+). Ponatinib inhibits Bcr-Abl in both its unmutated and mutated forms, including T315I, a missense mutation that makes Bcr-Abl extremely resistant to drug therapy. On December 14, 2012, the US FDA approved ponatinib for use in patients with Ph+ ALL and CML that was resistant or intolerant.

Biological Activity I Assay Protocols (From Reference)
Targets
VEGFR2 (IC50 = 1.5 nM); PDGFRα (IC50 = 1.1 nM); FGFR1 (IC50 = 2.2 nM); c-Kit (IC50 = 12.5 nM)
ln Vitro

AP24534, with an IC50 of 0.30 nM–2 nM, potently inhibits clinically significant mutants of the Abl kinase domain, including AblT315I and native Abl. Insulin receptor, CDK2/cyclin E, and members of the Aurora kinase family are not inhibited by AP24534. The proliferation of Ba/F3 cells expressing Bcr-Abl with an IC50 of 0.5 nM and Ba/F3 cells expressing a variety of Bcr-Abl mutants with an IC50 of 0.5 nM–36 nM is inhibited by AP24534. Apoptosis induction is correlated with AP24534's inhibition of proliferation.[1-2] AP24534, with an IC50 of 0.3 nM to 20 nM, potently inhibits receptor phosphorylation and cellular proliferation in leukemic cell lines containing activated forms of FLT3, KIT, FGFR1, and PDGFRα receptors. At less than 10 nM, AP24534 inhibits FLT3 signaling and induces apoptosis in MV4-11 (FLT3-ITD(+/+)) AML cells but not in RS4;11 (FLT3-ITD(–/–)) AML cells. Primary leukemic blasts from an AML patient who tests positive for FLT3-ITD are inhibited by AP24534 at an IC50 of 4 nM, but not those from patients whose AML expresses native FLT3.[3] AP24534 potently inhibits FGFR-mediated signaling and viability with an IC50 below 40 nM in Ba/F3 cells engineered to express activated FGFR1-4. AP24534 inhibits FGFR-mediated signaling with an IC50 of less than 40 nM and inhibits cell growth with an IC50 of 7 nM–181 nM in cell lines that represent multiple tumor types (endometrial, bladder, gastric, breast, lung, and colon) and contain FGFRs dysregulated by a variety of mechanisms.[4]

ln Vivo
AP24534 (2.5 mg/kg and 5 mg/kg) increases mice median survival in a mouse xenograft model of Ba/F3 cells expressing native Bcr-Abl. AP24534 (10 mg/kg–50 mg/kg) dramatically inhibits tumor growth in the Ba/F3 Bcr-AblT315I xenograft model. Phosphorylated Bcr-Abl and Phosphorylated CrkL are reduced in the tumors by AP24534 (30 mg/kg).[2]
Enzyme Assay
The impact of AP24534 (0-320 nM) on the activity of GST-Abl kinase is measured with a synthetic peptide substrate (Abltide: EAIYAAPFAKKK). In 25 μL reaction mixture, assays are run for 15 minutes at 30 °C. 8 mM MOPS (pH 7), 0.2 mM EDTA, 50 μM Abltide, 30 mM MgCl2, 10 mM β-glycerol phosphate, 1 mM EGTA, 0.002% Brij-35, 0.4 mM DTT, 0.2 mg/mL BSA, 0.4 mM sodium orthovanadate, 10 nM WT or mutant GST-Abl kinase, and 100 µM ATP/γ-32[P]ATP (5000 cpm/pmol). An immersion in 0.75% phosphoric acid is required to stop a reaction after part of the reaction mixture has been transferred onto a p81 phosphocellulose filter. Phosphate incorporation is measured using scintillation counting; filters are air dried after three rounds of washing in 0.75% phosphoric acid and rinsing in acetone. By removing the peptide substrate from the kinase reaction, background binding to the filters is taken into account for all results. Kinase assays come before time course experiments to determine the linear range of enzymatic activity.
Cell Assay
Ba/F3 cell lines are arranged in 96-well plates (4 × 103 cells/well) and given a 72-hour incubation period with AP24534. A methanethiosulfonate (MTS)-based viability assay (CellTiter96 Aqueous One Solution) is used to measure proliferation. Every value is compared to the drug-free control wells. The mean of three separate, quadruplicat experiments is used to report IC50 values.
Animal Protocol
Mice: In the Ba/F3 survival model, 100 μL of a 1×107 cells/mL suspension in serum-free medium is injected into the tail vein of female SCID mice expressing native BCR-ABL or BCR-ABLT315I. Mice are treated with vehicle (25 mM citrate buffer, pH 2.75), dasatinib, or ponatinib once daily for up to 19 days in a row starting 72 hours later. IACUC guidelines are followed when sacrificing morbid animals. Mice with evident splenomegaly from tumor cell infiltration were found during necropsy. The Kaplan-Meier method is utilized to analyze the survival data, and a Log-rank test is employed to assess statistical significance by comparing the survival time of each treatment group with that of the vehicle group. Ba/F3 BCR-ABLT315I cells, 100 μL of a 1×107 cells/mL cell suspension in serum-free medium, are subcutaneously inserted into the right flank of female nude mice for the Ba/F3 Tumor Model. The mice are assigned to treatment groups at random once the tumor volume averages around 500 mm3. For a maximum of 19 days, mice are given oral gavage once a day with either vehicle (25 mM citrate buffer, pH 2.75) or ponatinib. It computes the tumor volume (mm3). At the final measurement, mean tumor volume for treatment group/mean tumor volume for control group (%T/C) is calculated to determine tumor growth inhibition when the treatment period is over.
ADME/Pharmacokinetics
Absorption, Distribution and Excretion
The absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Food does not affect absorption of food. The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility. When 45 mg of ponatinib is given to cancer patients, the pharmacokinetic parameters are as follows: Cmax = 73 ng/mL; AUC = 1253 ng•hr/mL;
Ponatinib is mainly eliminated via feces. Following a single oral dose of [14C]-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the feces and approximately 5% in the urine.
After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the steady state volume of distribution is 1223 L. Ponatinib is a weak substrate for P-gp and ABCG2.
Ponatinib is greater than 99% bound to plasma proteins in vitro. The geometric mean (CV%) apparent steady state volume of distribution is 1223 liters (102%) following oral administration of Iclusig 45 mg once daily for 28 days in patients with cancer. Ponatinib is a weak substrate for both P-gp and ABCG2 [also known as BCRP] in vitro. Ponatinib is not a substrate for organic anion transporting polypeptides (OATP1B1, OATP1B3) and organic cation transporter 1 (OCT1) in vitro.
Exposure increased by approximately 90% (median) (range: 20% to 440%) between the first dose and presumed steady state. Ponatinib is mainly eliminated via feces. Following a single oral dose of (14)C-labeled ponatinib, approximately 87% of the radioactive dose is recovered in the feces and approximately 5% in the urine.
The absolute bioavailability of ponatinib is unknown. Peak concentrations of ponatinib are observed within 6 hours after Iclusig oral administration. Following ingestion of either a high-fat or low-fat meal by 22 healthy volunteers, plasma ponatinib exposures (AUC and Cmax) were not different when compared to fasting conditions. The aqueous solubility of ponatinib is pH dependent, with higher pH resulting in lower solubility.
Ponatinib was equally distributed into RBCs and plasma, and did not show preferential partitioning into red blood cells in mouse, rat, monkey, or human blood. Drug derived radioactivity was found in the brain, the Tmax being 48 hours.
For more Absorption, Distribution and Excretion (Complete) data for Ponatinib (6 total), please visit the HSDB record page.
Metabolism / Metabolites
At least 64% of a ponatinib dose undergoes phase I and phase II metabolism. CYP3A4 and to a lesser extent CYP2C8, CYP2D6 and CYP3A5 are involved in the phase I metabolism of ponatinib in vitro. Ponatinib is also metabolized by esterases and/or amidases.
In vivo, ponatinib was hydrolysed by non-specific esterases or amidases at the amide bond to an acid and aniline. AP24600 was the major metabolite in rat and human plasma but was a trace level metabolite in monkey plasma. In rat, monkey and human plasma, the amide hydrolysis metabolite AP24600 was 263%, < 1% and 58.4% of the ponatinib levels. In rats, the metabolism of ponatinib was mainly to the N-desmethyl metabolite AP24567, which was excreted in feces, and AP24600 (and its downstream metabolites) which was excreted in urine. In monkey feces drug-related radioactivity was present mostly as the parent compound or as N-desmethyl ponatinib (M42), hydroxy ponatinib (M31), a double lactam at piperazine moiety (M35) and N-oxide ponatinib (M36). In human feces, ponatinib accounted for 23.7% of the radioactivity and there was extensive metabolism of ponatinib. Other metabolites identified in human feces were hydroxy ponatinib, N-desmethyl ponatinib, and several minor metabolites resulting from two or more modifications.
At least 64% of a ponatinib dose undergoes phase I and phase II metabolism. CYP3A4 and to a lesser extent CYP2C8, CYP2D6 and CYP3A5 are involved in the phase I metabolism of ponatinib in vitro. Ponatinib is also metabolized by esterases and/or amidases.
Biological Half-Life
After oral administration of 45 mg ponatinib once daily for 28 days in cancer patients, the terminal elimination half-life is 24 hours (range of 12 - 66 hours).
The terminal half-life of ponatinib in plasma after an IV dose was 9.7 hr in the rat and 5.3 hr in the monkey.
The geometric mean (range) terminal elimination half-life of ponatinib was approximately 24 (12 to 66) hours following Iclusig 45 mg oral administration once daily for 28 days in patients with cancer.
Toxicity/Toxicokinetics
Hepatotoxicity
In large clinical trials, elevations in serum aminotransferase levels during ponatinib therapy occurred in up to 56% of patients and were above 5 times upper limit of normal (ULN) in 8% of patients. While these abnormalities were reversible in most patients, they were prolonged or severe in some. Instances of clinically apparent liver disease and progressive hepatic failure and death were reported in clinical trials of ponatinib, although the clinical features of the liver injury have not been well described. The latency until onset can be rapid and most cases have had a hepatocellular pattern of serum enzyme elevations. Because of the potential for serious hepatotoxicity, routine monitoring of liver tests is recommended during ponatinib therapy and dose modification or discontinuation recommended for ALT or AST elevations above 3 times ULN. Thus, ponatinib therapy is associated with a high rate of transient serum aminotransferase elevations and is reported to cause rare instances of severe hepatic injury, but there have been no cases described in the literature.
Reactivation of hepatitis B has been reported with imatinib and nilotinib therapy of CML, but not with ponatinib. Reactivation typically occurs in an HBsAg positive person treated with the tyrosine kinase inhibitor for 3 to 6 months, presenting with jaundice, marked serum aminotransferase elevations and an increase in HBV DNA levels. Reactivation of hepatitis B can be severe, and fatal instances have been reported after imatinib and nilotinib therapy. Screening of patients for HBsAg and anti-HBc is sometimes recommended before starting cancer chemotherapy and those with HBsAg offered prophylaxis with oral antiviral agents, such as lamivudine, tenofovir or entecavir. Whether reactivation occurs with ponatinib therapy is unknown.
Likelihood score: E* (unproven but suspected cause of clinically apparent liver injury).
Effects During Pregnancy and Lactation
◉ Summary of Use during Lactation
No information is available on the clinical use of ponatinib during breastfeeding. Because ponatinib is more than 99% bound to plasma proteins, the amount in milk is likely to be low. However, its half-life is about 24 hours and it might accumulate in the infant. National Comprehensive Cancer Network guidelines recommend avoiding breastfeeding during ponatinib therapy and the manufacturer recommends withholding breastfeeding for 6 days following the last dose.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Protein Binding
> 99% bound to plasma proteins.
Interactions
Ponatinib is a BCR-ABL tyrosine kinase inhibitor (TKI) approved for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in patients resistant or intolerant to prior TKIs. In vitro studies suggested that metabolism of ponatinib is partially mediated by CYP3A4. The effects of CYP3A4 inhibition on the pharmacokinetics of ponatinib and its CYP3A4-mediated metabolite, AP24567, were evaluated in a single-center, randomized, two-period, two-sequence crossover study in healthy volunteers. Subjects (N = 22) received two single doses (orally) of ponatinib 15 mg, once given alone and once coadministered with daily (5 days) ketoconazole 400 mg, a CYP3A4 inhibitor. Ponatinib plus ketoconazole increased ponatinib maximum plasma concentration (C(max)) and area under the concentration-time curve (AUC) compared with ponatinib alone. The estimated mean ratios for AUC0-8, AUC0-t, and C(max) indicated increased exposures to ponatinib of 78%, 70%, and 47%, respectively; exposure to AP24567 decreased by 71%. Exposure to AP24567 was marginal after ponatinib alone (no more than 4% of the exposure to ponatinib). These results suggest that caution should be exercised with the concurrent use of ponatinib and strong CYP3A4 inhibitors and that a ponatinib dose decrease to 30 mg daily, from the 45 mg daily starting dose, could be considered.
... Ponatinib at pharmacologically relevant concentrations produced synergistic cytotoxicity with ABCB1 and ABCG2 substrate chemotherapy drugs and enhanced apoptosis induced by these drugs, including daunorubicin, mitoxantrone, topotecan, and flavopiridol, in cells overexpressing these transport proteins. ...
References

[1]. Cancer Cell . 2009 Nov 6;16(5):401-12.

[2]. J Med Chem . 2010 Jun 24;53(12):4701-19.

[3]. Mol Cancer Ther . 2011 Jun;10(6):1028-35.

[4]. Mol Cancer Ther . 2012 Mar;11(3):690-9.

[5]. Blood . 2004 Oct 15;104(8):2532-9.

Additional Infomation
Therapeutic Uses
Antineoplastic Agents; Protein Kinase Inhibitors
Iclusig (ponatinib) is a kinase inhibitor indicated for the: Treatment of adult patients with T315I-positive chronic myeloid leukemia (CML) (chronic phase, accelerated phase, or blast phase) and T315I-positive Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). /Included in US product label/
Iclusig (ponatinib) is a kinase inhibitor indicated for the: Treatment of adult patients with chronic phase, accelerated phase, or blast phase chronic myeloid leukemia or Ph+ ALL for whom no other tyrosine kinase inhibitor (TKI) therapy is indicated. /Included in US product label/
Drug Warnings
/BOXED WARNING/ WARNING: VASCULAR OCCLUSION, HEART FAILURE, and HEPATOTOXICITY. Vascular Occlusion: Arterial and venous thrombosis and occlusions have occurred in at least 27% of Iclusig treated patients, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. Patients with and without cardiovascular risk factors, including patients age 50 years or younger, experienced these events. Monitor for evidence of thromboembolism and vascular occlusion. Interrupt or stop Iclusig immediately for vascular occlusion. A benefit-risk consideration should guide a decision to restart Iclusig therapy. Heart Failure: Heart failure, including fatalities, occurred in 8% of Iclusig-treated patients. Monitor cardiac function. Interrupt or stop Iclusig for new or worsening heart failure. Hepatotoxicity: Hepatotoxicity, liver failure and death have occurred in Iclusig-treated patients. Monitor hepatic function. Interrupt Iclusig if hepatotoxicity is suspected.
Hepatotoxicity and acute hepatic failure with fatal outcome have been reported in patients receiving ponatinib; liver biopsies predominantly showed hepatocellular necrosis.6 Fulminant hepatic failure resulting in death following 1 week of therapy was reported in one ponatinib-treated patient in the premarketing clinical trial. Elevations in serum aminotransferase (ALT or AST) concentrations were reported in 56% of patients receiving ponatinib in the premarketing clinical trial; median time to onset of these elevations was 46 days.6 Severe hepatotoxicity has been reported in all the disease cohorts; however, fatal cases have only been reported in patients with blast phase chronic myelogenous leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphocytic (lymphoblastic) leukemia (ALL).
Arterial thromboembolic events, sometimes serious or fatal, have been reported in patients receiving ponatinib. Specifically, cardiovascular, cerebrovascular, and peripheral vascular thrombosis, including fatal myocardial infarction and stroke, have occurred during ponatinib therapy. In the premarketing clinical trial, arterial thromboembolic events of any grade were reported in 11% of patients receiving ponatinib. Serious arterial thrombosis occurred in 8% of ponatinib-treated patients, and approximately 4.7% of patients required a revascularization procedure. The most common arterial thromboembolic event was myocardial infarction (MI) or worsening coronary artery disease; approximately half of these patients developed congestive heart failure concurrent with or subsequent to the myocardial ischemic event. Serious cerebrovascular events, including hemorrhagic conversion of the initial ischemic event and stenosis of large arterial vessels of the brain (e.g., carotid, vertebral, middle cerebral artery), have been reported. In the premarketing clinical trial, 3 of 449 ponatinib-treated patients developed digital or distal extremity necrosis; amputation was required in 2 patients with concomitant diabetes mellitus and peripheral arterial disease. Most (88%) patients who experienced a serious arterial thromboembolic event had one or more cardiovascular risk factors (e.g., MI, coronary artery disease, angina, stroke, transient ischemic attack (TIA), hypertension, diabetes mellitus, hyperlipidemia, cigarette smoking). If an arterial thromboembolic event occurs in a patient receiving ponatinib, interruption or discontinuance of therapy may be necessary. Venous thromboembolic events, including deep-vein thrombosis, pulmonary embolism, portal vein thrombosis, and retinal vein thrombosis, also have been reported in patients receiving ponatinib. Dosage modification or discontinuance of ponatinib therapy should be considered in patients who develop serious venous thromboembolism.
Ponatinib may cause fetal harm; the drug has been shown to be embryotoxic and fetotoxic in animals. There are no adequate and well-controlled studies in pregnant women. Pregnancy should be avoided during therapy. If used during pregnancy or if the patient becomes pregnant while receiving ponatinib, the patient should be apprised of the potential fetal hazard.
For more Drug Warnings (Complete) data for Ponatinib (22 total), please visit the HSDB record page.
These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
C29H27F3N6O
Molecular Weight
532.56
Exact Mass
532.219
Elemental Analysis
C, 65.40; H, 5.11; F, 10.70; N, 15.78; O, 3.00
CAS #
943319-70-8
Related CAS #
Ponatinib hydrochloride;1114544-31-8;Ponatinib-d8;1562993-37-6
PubChem CID
24826799
Appearance
white solid powder
Density
1.3±0.1 g/cm3
Melting Point
>160 °C
Index of Refraction
1.622
LogP
3.79
Hydrogen Bond Donor Count
1
Hydrogen Bond Acceptor Count
8
Rotatable Bond Count
6
Heavy Atom Count
39
Complexity
910
Defined Atom Stereocenter Count
0
SMILES
O=C(C1C=C(C#CC2N3C(C=CC=N3)=NC=2)C(C)=CC=1)NC1C=C(C(F)(F)F)C(CN2CCN(C)CC2)=CC=1
InChi Key
PHXJVRSECIGDHY-UHFFFAOYSA-N
InChi Code
InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39)
Chemical Name
3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]benzamide
Synonyms
AP-24534; AP24534; Ponatinib; AP 24534; Trade name: Iclusig
HS Tariff Code
2934.99.9001
Storage

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~30 mg/mL (~56.3 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

View More

Solubility in Formulation 3: 30% PEG400+0.5% Tween80+5% propylene glycol: 30mg/mL


 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.8777 mL 9.3886 mL 18.7772 mL
5 mM 0.3755 mL 1.8777 mL 3.7554 mL
10 mM 0.1878 mL 0.9389 mL 1.8777 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.

Calculator

Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box
g/mol

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
/

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)
+
+
+

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Clinical Trial Information
Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia
CTID: NCT04188405
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-11-25
Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)
CTID: NCT04747912
Phase: Phase 2    Status: Recruiting
Date: 2024-11-22
Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia
CTID: NCT03263572
Phase: Phase 2    Status: Recruiting
Date: 2024-11-20
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
CTID: NCT03589326
Phase: Phase 3    Status: Active, not recruiting
Date: 2024-10-31
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
CTID: NCT03934372
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-10-26
View More

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia
CTID: NCT05268003
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-22


Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
CTID: NCT04475731
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-10-22
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
CTID: NCT06207123
Phase: Phase 1/Phase 2    Status: Recruiting
Date: 2024-09-27
Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients with Philadelphia Chromosome-Positive And/or BCR-ABL Positive Acute Lymphoblastic Leukemia
CTID: NCT03147612
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-09-23
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
CTID: NCT06061094
Phase: Phase 2    Status: Recruiting
Date: 2024-09-19
Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)
CTID: NCT04160546
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-29
Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses
CTID: NCT02467270
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-08-21
Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
CTID: NCT04554459
Phase: Phase 2    Status: Terminated
Date: 2024-08-14
A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
CTID: NCT04501614
Phase: Phase 1/Phase 2    Status: Completed
Date: 2024-08-09
The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP
CTID: NCT06390306
Phase:    Status: Not yet recruiting
Date: 2024-06-21
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
CTID: NCT01570868
Phase: Phase 2    Status: Terminated
Date: 2024-06-13
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia
CTID: NCT01424982
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-05-28
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
CTID: NCT04070443
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-04-08
Study of Ponatinib (Iclusig) for Prevention of Relapse After Allogeneic Stem Cell Transplantation (Allo-SCT) in FLT3-ITD AML Patients
CTID: NCT03690115
Phase: Phase 2    Status: Active, not recruiting
Date: 2024-03-13
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
CTID: NCT03878524
Phase: Phase 1    Status: Terminated
Date: 2024-03-04
Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
CTID: NCT04845035
Phase: Phase 2    Status: Withdrawn
Date: 2024-02-22
Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients
CTID: NCT05306301
Phase: Phase 2    Status: Recruiting
Date: 2024-02-07
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
CTID: NCT04722848
Phase: Phase 3    Status: Recruiting
Date: 2024-02-07
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
CTID: NCT06175702
Phase:    Status: Not yet recruiting
Date: 2023-12-19
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
CTID: NCT04233346
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-11-01
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
CTID: NCT05286528
Phase:    Status: Completed
Date: 2023-10-27
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
CTID: NCT04591431
Phase: Phase 2    Status: Active, not recruiting
Date: 2023-10-03
Trial of Trametinib and Ponatinib in Patients With KRAS Mutant Advanced Non-Small Cell Lung Cancer
CTID: NCT03704688
Phase: Phase 1/Phase 2    Status: Completed
Date: 2023-09-21
Study in Patients With Chronic Leukemia
CTID: NCT03807479
Phase: Phase 2    Status: Terminated
Date: 2023-09-14
Iclusig PMS in CML or Ph+ALL Patients
CTID: NCT03709017
Phase:    Status: Unknown status
Date: 2022-12-07
Retrospective Evaluation of CML Patients in the National Compassionate Program
CTID: NCT02448095
Phase:    Status: Terminated
Date: 2022-10-26
Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia
CTID: NCT02776605
Phase: Phase 2    Status: Unknown status
Date: 2022-02-18
Study of Ponatinib
Ponatinib plus reduced-intensity chemotherapy in the first-line treatment of adult patients with Ph-positive acute lymphoblastic leukemia
CTID: null
Phase: Phase 2    Status: Completed
Date: 2020-10-06
A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of ponatinib (Iclusig®) in adult patients with minimal residual disease (MRD) in Philadelphia-Chromosome positive acute lymphoblastic leukemia
CTID: null
Phase: Phase 2    Status: Completed
Date: 2020-09-15
Cardiovascular assessment of Ponatinib as treatment option in chronic phase chronic myeloid leukemia after failure of Imatinib and Bosutinib (CarPAs)
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2020-09-10
The ROME trial from histology to target: the road to personalize target therapy and immunotherapy
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2020-07-08
WITH PONATINIB ON THE TRACK FOR TREATMENT-FREE-REMISSION
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2019-08-29
Trial Of Imatinib After Ponatinib Induction (Tipi) - A multicentre, open label phase II trial evaluating the safety and efficacy of ponatinib induction followed by imatinib maintenance in adult patients with Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), all risk scores, ≤65 years
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2019-07-16
'A Phase IIA Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin (IO) in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with positive Minimal Residual Disease before any Hematopoietics Stem Cell Transplantation'
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2019-07-08
TASTER- TArgeting STEm cell Resistance
CTID: null
Phase: Phase 2    Status: GB - no longer in EU/EEA
Date: 2019-05-28
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Effect of a One-Year Consolidation Treatment with Ponatinib 15 mg on Treatment Free-Remission Rate in Patients with Philadelphia-Positive Chronic Myeloid Leukemia, who had previously Achieved a Deep Molecular Response with Imatinib
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2018-11-15
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
CTID: null
Phase: Phase 3    Status: Trial now transitioned, Ongoing, Completed
Date: 2018-10-23
Phase 2 Clinical Trial with Ponatinib as a Second Line Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to prior First Line Tyrosine Kinase Inhibitor Treatment
CTID: null
Phase: Phase 2    Status: Completed
Date: 2018-10-05
OPEN LABEL PHASE 2 STUDY ON THE EFFICACY AND TOLERANCE OF A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS
CTID: null
Phase: Phase 2    Status: Trial now transitioned
Date: 2018-09-25
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
CTID: null
Phase: Phase 2    Status: Trial now transitioned, Ongoing, Prematurely Ended, Completed
Date: 2017-10-09
CONCURRENT PONATINIB WITH CHEMOTHERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2016-03-21
A Randomized, Open-label Study of Ponatinib Versus Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase Following Resistance to Imatinib
CTID: null
Phase: Phase 3    Status: GB - no longer in EU/EEA, Prematurely Ended, Completed
Date: 2015-11-03
Optimizing Ponatinib USe (OPUS). Studio GIMEMA di fase 2 sull¿efficacia e sul profilo di rischio di ponatinib, 30 mg al giorno, in pazienti con Leucemia Mieloide Cronica (LMC) in Fase Cronica, resistenti all¿Imatinib.
CTID: null
Phase: Phase 2    Status: Ongoing
Date: 2015-09-15
Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study
CTID: null
Phase: Phase 1    Status: GB - no longer in EU/EEA
Date: 2014-01-15
A national cancer research institute acute myeloid leukaemia working group pilot trial under the auspices of the cardiff experimental cancer medicine centre to establish the feasibility of combining the tyrosine kinase inhibitor, ponatinib with chemotherapy in patients with acute myeloid leukaemia with a flt3 mutation.
CTID: null
Phase: Phase 2    Status: Prematurely Ended
Date: 2013-10-30
A phase 3 randomised non-inferiority trial to evaluate the use of imatinib, nilotinib and ponatinib in patients with newly-diagnosed chronic phase chronic myeloid leukaemia
CTID: null
Phase: Phase 3    Status: Prematurely Ended
Date: 2013-09-19
Trattamento di prima linea della Leucemia Linfoblastica Acuta (LLA) Philadelphia positiva (Ph+)/BCR/ABL+ con un nuovo potente inibitore delle Tirosin-chinasi (TKI), AP24534 (Ponatinib). Studio multicentrico, esplorativo, di fase II in pazienti di et� superiore ai 60 anni o non idonei al programma intensivo di chemioterapia e trapianto delle cellule staminali.
CTID: null
Phase: Phase 2    Status: Temporarily Halted
Date: 2012-11-14
A Phase 3 Randomized, Open-Label Study of Ponatinib versus Imatinib in Adult Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
CTID: null
Phase: Phase 3    Status: Completed, Prematurely Ended
Date: 2012-10-04
A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients with Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia
CTID: null
Phase: Phase 2    Status: Completed
Date: 2011-02-21
Multicenter, Open-Label, Single Arm, Phase II Exploratory Study to Evaluate the Reinduction and second stop of TKI with Ponatinib in CML in Molecular Response (ResToP)
CTID: null
Phase: Phase 2    Status: Ongoing
Date:
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Ponatinib for the Treatment of Recurrent or Refractory Leukemias or Solid Tumors in Pediatric Participants
CTID: null
Phase: Phase 1, Phase 2    Status: Trial now transitioned, GB - no longer in EU/EEA, Ongoing
Date:

Biological Data
  • Ponatinib (AP24534)

  • Ponatinib (AP24534)
  • Ponatinib (AP24534)
Contact Us